For the first time, they demonstrated that ERK1/2 phosphorylation is altered in neocortex and hippocampus of FXS patients, suggesting that there is a chronic activation of the MAPK/ERK kinase (MEK)-ERK1/2 pathway; in addition they confirmed these results in cortical tissue obtained from Fmr1 KO mice (Wang et al., 2012). This evidence concerns the gene FMR1 and fragile X syndrome.